Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia

BMC Research Notes

Volumn 2, Issue , 2009, Pages

  Ascher Svanum, Haya ^a   Zhu, Baojin ^a   Faries, Douglas ^a   Furiak, Nicolas ^b   Montgomery, William ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Medical Decision Modeling Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 65649098979     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-2-6     Document Type: Article

References (20)

1. Practice guideline for the treatment of patients with schizophrenia, second edition. Lehman AF Lieberman JA Dixon LB McGlashan TH, Miller AL Perkins DO, Kreyenbuhl J. Am J Psychiatry 2004 161 1 56 10.1176/appi.ajp.161.1.1 15000267
2. Compliance with medication regimens for mental and physical disorders. Cramer JA Rosenheck R, Psychiatr Serv 1998 49 196 201 9575004
3. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Weiden PJ Kozma C, Grogg A Locklear J, Psychiatr Serv 2004 55 886 891 10.1176/appi.ps.55.8.886 15292538
4. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Valenstein M Copeland LA, Blow FC McCarthy JF, Zeber JE Gillon L, Bingham CR Stavenger T, Med Care 2002 40 630 639 10.1097/00005650-200208000-00002 12187177
5. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Gilmer TP Dolder CR Lacro JP Folsom DP, Lindamer L Garcia P, Jeste DV, Am J Psychiatry 2004 161 692 699 10.1176/appi.ajp.161.4.692 15056516
6. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. Ascher-Svanum H Faries DE, Zhu B Ernst FR, Swartz MS Swanson JW, J Clin Psychiatry 2006 67 453 460 16649833
7. A longitudinal study of medication non-adherence and hospitalization risk in schizophrenia. Law M Soumerai S, Ross-Degnan D Adams A, J Clin Psychiatry 2008 69 47 53 10.4088/JCP.v69n0107 18312037
8. Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs. Tunis SL Ascher-Svanum H, Stensland M Kinon BJ, Pharmacoeconomics 2004 22 1 8 10.2165/00019053-200422010-00001 14720078
9. Partial compliance and patient consequences in schizophrenia: our patients can do better. Keith SJ Kane JM, J Clin Psychiatry 2003 64 1308 1315 14658944
10. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Valenstein M Blow FC, Copeland LA McCarthy JF, Zeber JE Gillon L, Bingham CR Stavenger T, Schizophr Bull 2004 30 255 264 15279044
11. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ascher-Svanum H Zhu B, Faries D Ernst FR, Ann Gen Hosp Psychiatry 2004 3 11 10.1186/1475-2832-3-11 15175112
12. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. Faries D Ascher-Svanum H Zhu B Correll C, Kane J, BMC Psychiatry 2005 5 26 10.1186/1471-244X-5-26 15921508
13. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Kay SR Fiszbein A Opler LA, Schizophr Bull 1987 13 261 276 3616518
14. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Endicott J Spitzer RL, Fleiss JL Cohen J, Arch Gen Psychiatry 1976 33 766 771 938196
15. A rating scale for extrapyramidal side effects. Simpson GM Angus JW, Acta Psychiatr Scand Suppl 1970 212 11 19 10.1111/j.1600-0447.1970.tb02066.x 4917967
16. ECDEU Assessment Manual for Psychopharmacology. Guy W, Rockville, MD 1976
17. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Heinrichs DW Hanlon TE Carpenter WT Jr, Schizophr Bull 1984 10 388 398 6474101
18. The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care. Lehman AF Fischer EP Postrado L Delahanty J, Johnstone BM Russo PA, Crown WH, Schizophr Bull 2003 29 247 256 14552500
19. Classifying antipsychotic adherence using latent classes analysis: characteristic of non-adherent patients in the California Medicaid (MediCal) Program. Ahn J McCombs J, Jung C Croudace T, McDonnell D Ascher-Svanum H, Edgell E Shi L, Value Health 2008 11 48 56 18237360
20. Medication noncompliance and substance abuse among patients with schizophrenia. Owen RR Fischer EP, Booth BM Cuffel BJ, Psychiatr Serv 1996 47 853 858 8837158